Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome

It has been shown in previous studies that botulinum toxin type A (BTX-A) can effectively relieve the motor symptoms of Meige syndrome. However, its effect on non-motor symptoms (NMS) and quality of life (QoL) has not been comprehensively studied. This study aimed to explore the effects of BTX-A on...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in neurology Vol. 14; p. 1115482
Main Authors Zheng, Heqing, Wu, Lanxiang, Tian, Sheng, Liu, Mingxu, Zhan, Qingqing, Yu, Xinping, Xie, Yonggang, Zhong, Xianhui, Wu, Wei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.02.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:It has been shown in previous studies that botulinum toxin type A (BTX-A) can effectively relieve the motor symptoms of Meige syndrome. However, its effect on non-motor symptoms (NMS) and quality of life (QoL) has not been comprehensively studied. This study aimed to explore the effects of BTX-A on NMS and QoL and to clarify the relationship between changes in motor symptoms, NMS, and QoL after BTX-A. Seventy-five patients were recruited for the study. All patients were assessed by a series of clinical assessments before, one, and 3 months after BTX-A treatment. Dystonic symptoms, psychiatric disturbances, sleep disorders, and QoL were evaluated. After 1 and 3 months of BTX-A treatment, the scores of motor symptoms, anxiety, and depression were significantly decreased ( < 0.05). Except for general health, the scores of the other 36-item short-form health survey QoL subitems were significantly improved after BTX-A ( < 0.05). After 1 month of treatment, the changes in anxiety and depression were not correlated with changes in motor symptoms ( > 0.05). Still, they were negatively correlated with changes in physical functioning, role-physical and mental component summary QoL ( < 0.05). BTX-A effectively improved motor symptoms, anxiety, depression, and QoL. Anxiety and depression improvement did not correlate with motor symptom changes after BTX-A, and QoL improvements were strongly associated with psychiatric disturbances.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Kazuya Yoshida, National Hospital Organization Kyoto Medical Center, Japan
Reviewed by: Michael Hutchinson, St Vincent's University Hospital, Ireland; Matteo Costanzo, Sapienza University of Rome, Italy
This article was submitted to Movement Disorders, a section of the journal Frontiers in Neurology
ISSN:1664-2295
1664-2295
DOI:10.3389/fneur.2023.1115482